基于CiteSpace的关于乳腺癌PI3K信号通路的计量分析

Quantitative analysis of PI3K signaling pathway in breast cancer based on CiteSpace

目的利用CiteSpace软件对乳腺癌磷脂酰肌醇3-激酶(PI3K)信号通路的研究进展、发文情况进行分析。方法以“乳腺癌”和“PI3K”为主题词在Web of Science(WOS)数据库核心合集中检索2022年12月31日以前发表的相关文献,利用CiteSpace软件对检索的文章进行可视化分析。结果检索并筛选后共得到7590篇文献,自1994年以来年发文量逐年上升,其中发表数量最多的国家和机构分别是美国和德克萨斯大学安德森癌症研究中心,出现频次最高的三个关键词是“乳腺癌”“表达”“激活”。结论本文通过可视化分析提供了乳腺癌中PI3K通路的研究现状和趋势,目前该领域的研究热点聚焦于PI3K/AKT/mTOR信号通路药物的临床试验,PIK3CA抑制剂联合用药有望成为一种控制进展期乳腺癌的有效治疗策略。

Objective To analyze the research progress of phosphatidylinositol 3-kinase(PI3K)signaling pathway in breast cancer and the status of its publication by using CiteSpace software.Methods The related literature published before December 31,2022 were retrieved in the core collection of the Web of Science(WOS)database with"breast cancer"and"PI3K"as the subject words,and the retrieved articles were visually analyzed using CiteSpace software.Results A total of 7590 articles were obtained after searching and screening.Since 1994,the number of articles published has increased year by year.The countries and institutions with the largest number of publications are the United States and the University of Texas MD Anderson Cancer Center,respectively.The three keywords with the highest frequency were"breast cancer""expression"and"activation".Conclusion This paper provides the research status and trend of PI3K pathway in breast cancer through visual analysis.At present,the research hotspot in this field focuses on the clinical trials of PI3K/AKT/mTOR signaling pathway drugs.The combination of PIK3CA inhibitors is expected to become an effective treatment strategy to control advanced breast cancer.